<DOC>
	<DOCNO>NCT02051023</DOCNO>
	<brief_summary>Hypothesis : Fluorometholone ( FML ) 0.1 % eyedrop topically apply 4 time day 22 day efficient artificial tear ( Liquifilm ) dry eye disease ( DED ) ameliorate worsen disease exposure adverse control environment .</brief_summary>
	<brief_title>Efficacy Safety Fluorometholone ( FML ) Dry Eye Disease ( Keratoconjunctivitis Sicca )</brief_title>
	<detailed_description>There 4 visit 3 different day : Visit 1 ( V1 ) . Inclusion normalize control environment ( NCE ) Visit 2 ( V2 ) . 21 day post-treatment . Data collect NCE Visit 3 ( V3 ) . 21 day post-treatment . Data collect adverse control environment ( ACE ) Visit 4 ( V4 ) . 22 day post-treatment . Recovery visit ACE . Data collect NCE</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Fluorometholone</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Age &gt; 18 year Signed informed consent Subjects refer worsen pathology expose adverse environmental condition daily life Fluorescein corneal stain ≥ 1in Oxford Scale Ocular surface disease index ( OSDI ) test &gt; 12 Tear breakup Time ( TBT ) ≤ 7 second eyes Schirmer test without anesthesia ≤ 10 mm 5 minute eye Any concomitant medication may affect dry eye syndrome , ocular surface vision , must start least 3 month screen visit , change dose expect study duration . Best correct visual acuity least 0.1 logMar 6 meter eye Current use ophthalmic artificial tear study inclusion . Signed informed consent Signed data protection consent Sensitivity know intolerance product use study Previous severe ocular inflammation infection 6 previous month study inclusion Any ocular pathology dry eye syndrome atopic keratoconjunctivitis Any ocular surgery trauma may affect corneal sensitivity / normal tear distribution ( refractive cataract surgery ) 6 previous month ocular systemic surgery plan study duration may affect study assess principal investigator . Use contact lenses 3 previous month study inclusion Use topical medication pathology dry eye syndrome . Any ocular topical treatment dry eye syndrome corticosteroid non steroid antiinflammatory drug must stop 1 month study inclusion . Any treatment topical cyclosporin must stop 3 month study inclusion . Any uncontrolled severe systemic disease may affect eye ( except Sjögren Syndrome ) Start , discontinuation dose change study antihistaminic , cholinergic agent , beta blocker , antidepressant systemic medication potential effect tear film . Start systemic treatment may affect dry eye syndrome , vision , ocular surface intraocular pressure 3 previous month study inclusion . Surgical / non surgical tear point occlusion 3 previous month study inclusion prevision study duration procedure . Cup / disc ratio &gt; 0.6 History intraocular pressure &gt; 22 mm Hg within 2 month previous study inclusion Pregnancy breastfeed woman Inclusion another research study previous 30 day study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>keratoconjunctivitis sicca</keyword>
	<keyword>dry eye</keyword>
	<keyword>dry eye syndrome</keyword>
	<keyword>dry eye disease</keyword>
	<keyword>steroid</keyword>
</DOC>